Corvus Pharmaceuticals, Inc. has expanded its clinical collaboration with Genentech, a member of the Roche Group, for CPI-444 in combination with atezolizumab (Tecentriq) to be evaluated in a Phase Ib/II clinical study as second-line therapy in non-small cell lung cancer (NSCLC). The study will be part of MORPHEUS, Genentech’s novel cancer immunotherapy platform established to develop immunotherapy combination therapies more rapidly and efficiently. CPI-444, Corvus’ lead product, is a selecti...